Full Press Release Details
Eidos Therapeutics Initiates ATTRibute-CM, A Phase 3 Study Of AG10 In ATTR-CM With Registrational 12-month Endpoint.
BBIO
Eidos Therapeutics Initiates ATTRibute-CM, A Phase 3 Study Of AG10 In ATTR-CM With Registrational 12-month Endpoint
Key Takeaway: Eidos Therapeutics Initiates ATTRibute-CM, A Phase 3 Study Of AG10 In ATTR-CM With Registrational 12-month Endpoint
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis